Eikon Therapeutics

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 160 adults with certain ca…

This study tests a new drug called EIK1001 added to standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who haven't had treatment yet. About 70 participants will be enrolled to see if the combination is safe and shrinks tumor…

This study tests whether adding the experimental drug EIK1001 to the standard immunotherapy pembrolizumab helps people with advanced melanoma live longer without their cancer growing. About 740 adults with stage 3 or 4 melanoma that cannot be removed by surgery will receive eithe…

This study tests a new drug called IMP1734 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 156 adults with certain breast, ovarian, or prost…